BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Treatment-free remission (TFR; that is, sustained major molecular response (MMR; BCR-ABL1⩽0.1% on the International Scale (BCR-ABL1IS)) or deep molecular response (DMR) after stopping tyrosine kinase inhibitor (TKI) therapy) is an emerging treatment goal for patients with chronic myeloid leukemia in chronic phase (CML-CP).